Elevated serum levels of transforming growth factor beta1 in Epstein-Barr virus-associated nasopharyngeal carcinoma patients.
about
Quantification of Epstein-Barr virus DNA load, interleukin-6, interleukin-10, transforming growth factor-beta1 and stem cell factor in plasma of patients with nasopharyngeal carcinomaElevated serum transforming growth factor beta1 levels in Epstein-Barr virus-associated diseases and their correlation with virus-specific immunoglobulin A (IgA) and IgM.Upregulation of MiR-155 in nasopharyngeal carcinoma is partly driven by LMP1 and LMP2A and downregulates a negative prognostic marker JMJD1A.Treatment strategies for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH).Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinomaElevated levels of circulating interleukin-18 in human immunodeficiency virus-infected individuals: role of peripheral blood mononuclear cells and implications for AIDS pathogenesis.The impact of smoking on the clinical outcome of locoregionally advanced nasopharyngeal carcinoma after chemoradiotherapyLimb-bud and Heart (LBH) functions as a tumor suppressor of nasopharyngeal carcinoma by inducing G1/S cell cycle arrest.Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemiaMethylation and Expression of Retinoblastoma and Transforming Growth Factor-β1 Genes in Epstein-Barr Virus-Associated and -Negative Gastric Carcinomas.Decreased expression of the NKG2D ligand ULBP4 may be an indicator of poor prognosis in patients with nasopharyngeal carcinoma.Upregulation of flotillin-1 promotes invasion and metastasis by activating TGF-β signaling in nasopharyngeal carcinoma.An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation.Epstein-Barr virus infection in immortalized nasopharyngeal epithelial cells: regulation of infection and phenotypic characterization.TGF-beta inhibition of CTL re-stimulation requires accessory cells and induces peroxisome-proliferator-activated receptor-gamma (PPAR-gamma).A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells.The immunologic advantage of recurrent nasopharyngeal carcinoma from the viewpoint of Galectin-9/Tim-3-related changes in the tumour microenvironment.Increase in circulating Foxp3+CD4+CD25(high) regulatory T cells in nasopharyngeal carcinoma patients.Epstein-Barr virus infection and plasma transforming growth factor-beta1 levels in head and neck cancers.Dysregulation of the MiR-449b target TGFBI alters the TGFβ pathway to induce cisplatin resistance in nasopharyngeal carcinoma.Regulation of transforming growth factor is involved in the efficacy of combined 5-fluorouracil and interferon alpha-2b therapy of advanced hepatocellular carcinoma.
P2860
Q28200526-7C45EBF5-F155-4038-8CC4-7EFC400914BBQ33799292-EA4F1A83-FCBA-4632-AEBB-E2E9F2225A67Q33889404-135957EC-EDE9-472E-B3CB-87F67D75B8BFQ34024242-E072C97F-AA04-4565-A5A5-0108BB6B73A9Q34089491-0489BC9B-D558-4291-B811-215D1C57E179Q34353054-4232A997-72CF-4F07-924E-2CF75F9AE09CQ34610984-FFD8150A-7C01-492B-9C21-18CA84BA29EAQ34820689-65023C2D-CE48-48D7-AD1C-A13E0AD5B5C4Q35609315-A1AEE020-66BC-49BD-A546-C618C1F815E9Q36248454-4142E4B8-D064-4B1D-A123-310E2B0293E3Q38376092-A70422F2-F8E5-44AA-9260-606153D73605Q38383190-E85178FC-4D97-4982-BB87-A4C57EDDFCA4Q39279923-4C95D725-5BD7-4954-B935-97487F7D38D0Q39749474-16E3B3D6-3B59-418B-867F-8BA6B9A58B68Q40247364-BF6F6560-49A3-4335-A46C-0DAE4E1B22BFQ40605843-34CB8EDF-8B6E-42E6-BBB5-492FA4C91DB4Q41607185-708F2F75-787C-4A18-AB8A-B3D78168815DQ41781757-F6A6C150-4D3B-4D84-A8E3-20398C92B078Q45391927-0C007CC8-1FBB-45CD-BB33-6532C4BFE03BQ55001674-3D6B1F19-B941-43FF-A24E-F9D8D9F6A8D6Q55216911-33F2E559-D9A7-41E9-A4DC-530DA80B98BA
P2860
Elevated serum levels of transforming growth factor beta1 in Epstein-Barr virus-associated nasopharyngeal carcinoma patients.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Elevated serum levels of trans ...... pharyngeal carcinoma patients.
@en
Elevated serum levels of trans ...... pharyngeal carcinoma patients.
@nl
type
label
Elevated serum levels of trans ...... pharyngeal carcinoma patients.
@en
Elevated serum levels of trans ...... pharyngeal carcinoma patients.
@nl
prefLabel
Elevated serum levels of trans ...... pharyngeal carcinoma patients.
@en
Elevated serum levels of trans ...... pharyngeal carcinoma patients.
@nl
P2093
P1476
Elevated serum levels of trans ...... opharyngeal carcinoma patients
@en
P2093
P304
P356
10.1002/(SICI)1097-0215(19990820)84:4<396::AID-IJC11>3.0.CO;2-#
P50
P577
1999-08-01T00:00:00Z